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JaPanese RePResentation in Leading geneRaL Medicine and Basic 
science JouRnaLs: a coMPaRison of two decades
Takahashi O.
St.Luke’s International Hospital, Tokyo, Japan
Objectives: During 1991-2000, Japan contribution to the top basic and clinical sci-
ence journals was less than 1% and 3%, respectively. The objective of this study was 
to compare the Japanese representation in 7 major general medicine journals and 
6 basic science journals between the years 1991-2000 and 2001-2010. MethOds: 
Retrospective observational study. We measured the frequency of journal article 
publications in PubMed from Japan in both seven high-impact general medical and 
internal medicine journals and six high-impact basic science journals using Boolean 
operators to connect name of the journal, year of publication and corresponding 
authors’ affiliation with different universities, cities and places in Japan. Results: 
Japan represented 0.66% (260/39,255) and 0.74% (265/36,038) of journal articles in 7 
of the top general medicine journals during 1991-2000 and 2001-2010, respectively. 
In contrast, the respective representation in 6 of the top basic science journals was 
2.51% (849/33,779) and 3.60% (1364/37,908), respectively. Overall, we observed that 
the proportion of Japan-originated articles published in the top general medicine 
journals during 2001-2010 remained unchanged compared to 1991-2000 (P= 0.255). 
However, the Japanese representation in basic science journals during 2001-2010 
increased significantly compared to 1991-2000 (P< 0.001). Japanese representation in 
basic science journals had an upward trend during the 1991-2000 period (P< 0.001) 
but remained flat during 2001-2010 (P= 0.177). In contrast, the trend of Japanese 
representation in general medicine journals remained flat during the period of 
1991-2000 (P= 0.273) but exhibited a marginally downward trend during 2001-2010 
(P= 0.073). cOnclusiOns: Overall, the Japanese representation in top general 
medicine journals has remained negligible and unchanged over the last two dec-
ades. Representation in basic science journals remained unchanged during the 
time period of 2001-2010, although it had shown an upward trend during the years 
1991-2000. Interventional measures are needed to address these trends.
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deteRMinants of PRoMPt access to HeaLtH caRe in cHPs PRogRaMMe 
in RuRaL coMMunities of BawJiase, gHana
Nuamah Buruwaa G.1, Agyei-Baffour P.2
1Korle Bu Teaching Hospital, Accra, Ghana, 2Kwame Nkrumah Univeristy of Science and 
Technology, Kumasi, Ghana
Objectives: Prompt access to effective health care is a priority in the develop-
mental agenda of Ghana yet only 20% of people who actually need health care have 
it. Evidence on the determinants of prompt access to health care in these CHPS 
programme is woefully inadequate. The study sought to assess the factors that 
influence prompt access to health care in CHPS settings. MethOds: A descriptive 
cross sectional study was conducted in 2011 with 230 respondents within the CHPS 
zones of Bawjiase Sub-district, Central region of Ghana. Data was collected on using 
structured questionnaire and analyzed using SPSS version 19 software. Logistic 
regression was run to access the correlation of the determinants on prompt access 
to health care in CHPS settings at 95% confidence interval. Results: We identi-
fied that, factors which play a major role in prompt access of CHPS programme 
within the CHPS zones of Bawjiase sub - district include geographical accessibility 
(chi square = 33.57; p = 0.000) and service characteristics (chi square = 19.17; p = 
0.001). Economic accessibility however, had no influence (chi square = 123; p = 
0.975) on prompt access to CHPS programme. Factors which had strong influence 
on prompt access of CHPS programmes were age (chi square = 12.39; p = 0.015), 
sex (chi square = 15.25; p = 0.000), marital status (chi square = 31.56; p = 0.000), 
education level (chi square = 28.49; p = 0.000) and occupation (chi square = 33.56; p 
= 0.000). cOnclusiOns: The study concludes that geographical proximity, service 
characteristics and individuals’ background factors influence prompt access to qual-
ity health care in rural CHPS setting.
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astRoLogicaL signs and HeaLtH PRoBLeMs; deMonstRating tHe 
MuLtiPLe coMPaRisons PRoBLeM
Vegter S., van Boven J.F., Pechlivanoglou P., Rozenbaum M.H., Stevanovic J., Le H.H.
University of Groningen, Groningen, The Netherlands
Objectives: Astrological signs have been linked to numerous health problems, 
not only in pseudoscientific but also in high impact, peer-reviewed scientific lit-
erature. The aim of this study was to use a large prescription database to assess 
associations between astrological star signs and health problems. This study may 
demonstrate important statistical issues that arise when doing multiple compari-
sons. MethOds: For this cross-sectional study, patient and drug data were collected 
from a large prescription database in The Netherlands. Patients were followed for 
one year, starting from their birthday in 2010. Outcomes were drug prescriptions 
for one of four health problems: cardiovascular disease, depression, erectile dys-
function in men and fertility problems in women. The “determinant” was patients’ 
astrological sign (based on Western-culture horoscope). Differences in prevalence 
rates between star signs were tested using logistic regression, adjusted for age 
and gender. Significance was set at P= 0.05. Results: Almost 300,000 persons were 
included for analysis. In our analysis, persons born under the star sign Aquarius 
were less likely to suffer from cardiovascular disease (P= 0.001), whereas patients 
born under Scorpio or Sagittarius were more likely (P= 0.011 and P= 0.017). There were 
no effects on depression or erection dysfunctions. Women born under Gemini were 
37% less likely to use fertility drugs (P= 0.016). cOnclusiOns: This study found 
several associations between star signs and health problems, none of which had any 
biologic plausibility. Interestingly, datasets filled with randomly generated star sign 
data also resulted in significant findings. Multiple comparisons without prespeci-
fied hypotheses, biological plausibility and adjustments for familywise error rates, 
can lead to false-positive findings. Multiple comparisons are common in outcomes 
research, appropriate use of statistics therefore is important.
published literature, HTA reports, and third-party websites, to identify the critical 
path and data most valuable to reimbursement decision making. We conducted 26 
qualitative one-on-one interviews with payer decision makers in the EU-5: 12 key 
opinion leaders, 4 laboratory directors, and 10 academic health economists and HTA 
advisors. Results: Reimbursement is critical to rapid adoption of new technolo-
gies. There are multiple appropriate access pathways for various theatres of care 
(e.g., outpatient office/clinic, inpatient, emergency), all with varying requirements 
and value drivers. Payment for new diagnostic tests typically is handled regionally 
or locally; treating physicians and medical societies can influence these budget 
decisions. Shared financial agreements or risk-sharing scenarios may speed intro-
duction of a new POC test. Test reimbursement processes may differ for inpatient 
versus outpatient use. Currently, the evidence hurdle for a POC test is not as high 
as for prescription medicines. cOnclusiOns: Market access for a POC test varies 
across and within countries; adequate data to meet decision makers’ needs is not 
well understood. No roadmap exists for navigation of the critical path for POC tests, 
and evidence requirements in the EU are not well established. Access for a POC test 
will be complex; regardless of pathway, decisions regarding reimbursement and 
adoption of new technology are diverse and dispersed across and within countries 
with varying levels of required evidence.
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VaLue of Life: as PeRceiVed By PHysicians and tHe geneRaL PuBLic
Tichopad A., Zigmond J.
CEEOR s.r.o., Prague, Czech Republic
Objectives: With the advancing process of HTA in the Czech Republic question 
emerged such as what is the willingness to pay (WTP) for health and life as well 
as what is the general awareness of the national health care policy and health 
economics. So far all estimations of WTP were largely based on academic deduc-
tions, thus we adopted a previously published approach to estimate the empirical 
WTP. MethOds: A total of 381 doctors of 15 specializations and 500 respondents 
from general population, both matching the CZ demography, were interviewed 
online. Doctors were asked directly to suggest reasonable WTP per equivalent of 
QALY. The general public was interview using the dichotomous double bounded 
choice method. The value of WTP, including 95% confidence interval, was deter-
mined using proc lifereg of the SAS system that allowed estimating averages for 
interval data. Optimal parametric extrapolation of the data was chosen based on 
the minimum value of Akaike’s information criterion (AIC). Results: Economics 
is the last criterion considered as important by doctors following the quality of life, 
clinical parameters and ethical/social aspects. Doctors not rejecting the concept 
of paying for health (28%) produced median of CZK 700,000 (EUR 27,129) to be an 
adequate payment for an extra year in full health, representing one QALY. General 
population suggested CZK 18.4 million (EUR 731,110) as an adequate WTP to be paid 
by the national health insurance fund, largely in contrast to only CZK 177,000 (EUR 
6859) as suggested for the pay-of-pocket WTP. cOnclusiOns: The awareness about 
health economics and its methodology is rather low among doctors and general 
public. While those medical doctors who expressed understanding for the concept 
of WTP and QALY suggested a value similar with the implicit WTP of CZK 1,000,000 
(EUR 38,756) general public suggested extreme WTP from public budget, reflecting 
distant position of the public.
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Objectives: Applications to run clinical trials in Europe have been falling 
since 2007. Costs, speed of approvals, and shortcomings of European Clinical 
Trial Directive (CTD) are commonly held responsible. However, there is no hard 
evidence on the actual weight of these factors, nor are policy recommenda-
tions typically founded on a research-based understanding of factors impact-
ing trial site selection. Indeed, borrowing from the rigour of its own discipline, 
medical policy decisions ought to be “evidence-based”. MethOds: The SAT-EU 
StudyTM was an anonymous, cross-sectional Web-based survey designed to 
systematically assess factors impacting European clinical trial site selection. 
It explored 19 factors across investigator-, hospital-, and environment-driven 
criteria, and costs. It also surveyed perceptions of the European trial environ-
ment. Clinical Research Organizations (CROs), academic Clinical Trial Units 
(CTUs), and Industry were invited to respond. OUTCOME MEASURES: Primary: 
Weight assigned to each factor hypothesized to impact trial site selection and 
trial incidence; Secondary: Desirability of twelve European countries to run 
clinical trials Results: Responses were obtained from 485 professionals in 34 
countries: 49% from BioPharma, 40% from CTUs or CROs. Investigator-, environ-
ment-, and hospital-dependent factors were rated highly important, costs being 
less important (P< 0.0001). Within environment-driven criteria, pool of eligible 
patients, speed of approvals, and presence of disease-management networks 
were significantly more important than costs or government financial incentives 
(P< 0.0001). Germany, UK, and The Netherlands were rated the best trial markets 
(P< 0.0001). cOnclusiOns: Fostering European clinical research does not require 
additional government spending or a revamping of the clinical trial cost structure. 
Rather, it requires greater visibility of centres of excellence and the harmonised 
national adoption of recently approved revisions to the CTD. Carefully crafted 
harmonization of approvals, including aligned hospital contracting, speedier trial 
authorization and greater visibility of disease networks may bring significantly 
more clinical research to Europe and stimulate growth.
